Key result
Saroglitazar is linked to a ~63 mg/dL reduction in triglycerides across varying kidney function.
Why the study?
Does saroglitazar 4 mg improve lipid and glycemic parameters in patients with metabolic disease across varying degrees of renal function?
Observational (n=614)
Does saroglitazar 4 mg improve lipid and glycemic parameters in patients with metabolic disease across varying degrees of renal function?
Saroglitazar 4 mg is associated with significant improvements in lipid and glycemic profiles across various levels of kidney function in patients with metabolic disease.
Purpose Metabolic dysfunction and chronic kidney disease (CKD) often coexist, presenting therapeutic challenges. Saroglitazar, a dual proliferator-activated receptor (PPAR)-α/γ agonist, shows promising effects in managing dyslipidemia and glycemic abnormalities; however, real-world evidence (RWE) is limited across varying degrees of renal function. This study evaluated the effectiveness and safety of saroglitazar (4 mg) in patients with metabolic disease in India stratified by estimated glomerular filtration rate (eGFR). Methods This retrospective observational study analyzed the electronic medical records (EMRs) of 614 patients with metabolic disorders prescribed saroglitazar. Changes in lipid and glycemic parameters, liver enzymes, and renal function were assessed from baseline to follow-up (minimum 90 days) across eGFR categories. Results A total of 614 patients were included. Metabolic and cardiac disorders were the most common conditions at baseline. Significant reductions were observed in triglycerides (TG, -62.68 mg/dL), low-density lipoproteins (LDL, -7.03 mg/dL), and glycosylated hemoglobin (HbA1c, -0.76%) in the overall population (p < 0.001), with similar reductions in patients with eGFR ≥90 mL/min/1.73 m² and 60-89.99 mL/min/1.73 m². Patients with hepatic conditions showed a significant decrease in aspartate transaminase (AST) and alanine transaminase (ALT) levels. eGFR levels remained stable across categories. Saroglitazar was associated with a low incidence of adverse events, including asthenia (n = 12, 1.95%) and pyrexia (n = 6, 0.97%). Conclusion Saroglitazar was associated with improved lipid and glycemic profiles across various levels of kidney function, with limited safety concerns. These real-world findings suggest the potential metabolic benefits of saroglitazar in Indian patients with metabolic abnormalities, across diverse renal functions.
No takes yet. Share an insight, caveat, or question.
Tripathi et al. (2026) conducted an observational in Metabolic disease (n=614). Saroglitazar was evaluated on Changes in triglycerides, low-density lipoproteins, and glycosylated hemoglobin (MD -62.68 mg/dL for triglycerides, p=<0.001). Saroglitazar exposure was associated with significant reductions in triglycerides (-62.68 mg/dL), LDL (-7.03 mg/dL), and HbA1c (-0.76%) across varying levels of kidney function (p < 0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: